Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131657 | 1.00 | FDPS (0.50) | FDPSBLMTDP1PPARDBTN3A1 | |
| SCHEMBL6562094 | 0.88 | PPARD (0.46) | FDPSBLMTDP1PPARDLPAR3 | |
| SCHEMBL12259745 | 0.87 | FDPS (0.43) | FDPSBLMTDP1PPARDBTN3A1 | |
| SCHEMBL28063817 | 0.85 | PPARD (0.44) | FDPSBLMTDP1PPARDLPAR3 | |
| SCHEMBL28299764 | 0.80 | PPARD (0.41) | FDPSBLMTDP1PPARDLPAR3 | |
| SCHEMBL8529848 | 0.78 | PPARD (0.39) | FDPSBLMTDP1PPARDKDM4E | |
| SCHEMBL13459272 | 0.78 | BTN3A1 (0.48) | FDPSBLMTDP1PPARDBTN3A1 | |
| Pyrophosphoric Acid SCHEMBL5822274 | 0.78 | FDPS (0.71) | FDPSBLMTDP1PPARDBTN3A1 | |
| Pyrophosphoric Acid SCHEMBL2426695 | 0.78 | FDPS (0.71) | FDPSBLMTDP1PPARDBTN3A1 | |
| SCHEMBL1661755 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017127430-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-9683330-B2 | Wet paper web transfer belt | ICHIKAWA CO., LTD (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9589814-B2 | Semiconductor device packages and methods of manufacturing the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20160244514-A1 | Humanized Antibody | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160213763-A1 | NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF | ACADEMIA SINICA (TW) | 2016-07-28 | — | — | US | disclosed |
| US-9211300-B2 | 4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015017713-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014179765-A2 | NOVEL HUMAN MIRNAS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF HUMAN CONDITIONS AND DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014137454-A1 | METHODS AND COMPOSITIONS TO INHIBIT THE ASSEMBLAGE OF MICROBIAL CELLS IRREVERSIBLY ASSOCIATED WITH SURFACES OF MEDICAL DEVICES | TYRX, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-8779119-B2 | Metal salt of crosslinked cellulose derivative | JNC CORPORATION (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-06-26 | — | — | US | disclosed |
| US-8455628-B2 | PP1 ligands | INTREXON CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130064843-A1 | Identification of conserved peptide blocks in homologous polypeptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100317844-A1 | METAL SALT OF CROSSLINKED CELLULOSE DERIVATIVE | CHISSO CORPORATION | 2010-12-16 | — | — | US | disclosed |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| US-20080108569-A1 | PH domain leucine-rich repeat protin phosphatase (PHLPP), inactivates Akt (protein kinase B) by directly dephosphorylating the hydrophobic domain of the C-terminus; prevents cancer, Alzheimer's disease, diabetes, diabetic macular edema and cardiovascular disease, antiapoptosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | FDPS 475/4885BLM 806/4885TDP1 2616/4885 |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | FDPS 4547/4885BLM 4357/4885TDP1 1907/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | FDPS 2940/4885BLM 4175/4885TDP1 1449/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | FDPS 1119/4885BLM 1318/4885TDP1 777/4885 |
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | FBL, HNRNPLL, SLC28A1 | FDPS 937/4885BLM 1357/4885TDP1 694/4885 |
| US-20160213763-A1 | NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF | B3GAT3, ST6GAL1, STT3A | FDPS 1237/4885BLM 3220/4885TDP1 959/4885 |
| US-20100317844-A1 | METAL SALT OF CROSSLINKED CELLULOSE DERIVATIVE | OGA, SLC5A1, OSTC | FDPS 4825/4885BLM 1570/4885TDP1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.